Effect of semaglutide treatment on chronic kidney disease in patients with type 2 diabetes: results from the FLOW study
Authors:
Pavlína Piťhová
Published in:
AtheroRev 2024; 9(2): 103-104
Category:
Sources
Perkovic V, Tuttle KR, Rossing P et al. [FLOW Trial Committees and Investigators]. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024; 391(2): 109–121. Dostupné z DOI: <https://doi 10.1056/NEJMoa2403347>.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsArticle was published in
Athero Review
2024 Issue 2
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Memantine in Dementia Therapy – Current Findings and Possible Future Applications
- Metamizole vs. Tramadol in Postoperative Analgesia
- Memantine Eases Daily Life for Patients and Caregivers
Most read in this issue
- Diagnosis and treatment of hyperuricemia in cardiovascular prevention based on the pathophysiological mechanism of its occurrence: expert consensus of Czech and Slovak experts 2024
- Bempedoic acid – a new player in the field of hypolipidemic therapy
- The current role of lipoprotein apheresis in the context of new recommendations for hypolipidemic pharmacotherapy
- Effect of semaglutide treatment on chronic kidney disease in patients with type 2 diabetes: results from the FLOW study